Fulgent Genetics (FLGT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $71.7 million, with core revenue up 9% year-over-year, driven by growth in precision diagnostics and strong demand in reproductive health and hereditary cancer screening, including a $99 million VA contract over five years.

• Net loss attributable to the company was $14.6 million ($0.48 per share), while non-GAAP income was $9.4 million ($0.31 per share); adjusted EBITDA was $0.4 million.

• Therapeutic development advanced with FID-007 entering Phase II trials and FID-022 progressing toward IND application, with FID-007 showing a 45% ORR and 72% DCR in HNSCC Phase 1/1b trials.

• Investments in technology, digital pathology, and AI improved operational efficiency and quality, with 80% of slides digitized in Q3.

• Cash, cash equivalents, and marketable securities totaled $815.4 million as of September 30, 2024.

Financial highlights

• Q3 2024 revenue was $71.7 million, down from $84.7 million in Q3 2023, with negligible COVID-19 testing revenue.

• Non-GAAP gross margin was 40% (GAAP: 37.3%), and non-GAAP operating margin was -5.8% in Q3 2024.

• Adjusted EBITDA was $0.4 million, down from $18.1 million in Q3 2023.

• Non-GAAP income for the quarter was $9.4 million, or $0.31 per share, excluding certain charges.

• A $10.1 million impairment on Helio Health investment negatively impacted EPS by 33%.

Outlook and guidance

• 2024 core revenue expected to be approximately $280 million, representing 7% year-over-year growth.

• Non-GAAP gross margins for 2024 projected in the high 30% range, targeting 40% by year-end.

• Non-GAAP operating margin for 2024 expected at approximately -12% due to ongoing investments.

• Full-year 2024 non-GAAP EPS guidance improved to $0.33 per share, up from a prior loss estimate.

• Year-end 2024 cash, cash equivalents, and investments projected at approximately $800 million, subject to variability from stock repurchases or other expenditures.